Hexokinase-2 bound to mitochondria: Cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy

Seminars in Cancer Biology

Volumn 19, Issue 1, 2009, Pages 17-24

  Mathupala, Saroj P ^a   Ko, Young H ^c   Pedersen, Peter L ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cancer Cure Med   (United States)

Author keywords

3 Bromopyruvate; Cancer; Cancer therapy; Hexokinase 2; PET analysis; Warburg

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUCOSE; HEXOKINASE; PROTEIN HEXOKINASE 2; PYRUVIC ACID; UNCLASSIFIED DRUG;

CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER THERAPY; CELL IMMORTALIZATION; CELL METABOLISM; ENERGY METABOLISM; ENZYME BINDING; ENZYME INHIBITION; GENE AMPLIFICATION; GENE CONTROL; GLYCOLYSIS; HEPATOMA CELL; METASTASIS; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW;

ADENOSINE TRIPHOSPHATE; ANIMALS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOLYSIS; HEXOKINASE; HUMANS; MITOCHONDRIA; NEOPLASMS; PHOSPHORYLATION; PROTEIN ISOFORMS; PYRUVATES;

EID: 60249083822     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2008.11.006     Document Type: Review

References (60)

1. Wilson J.E. Hexokinases. Rev Physiol Biochem Pharmacol 126 (1995) 65-198
2. Wilson J.E. An introduction to the isoenzymes of mammalian hexokinase types I-III. Biochem Soc Trans 25 (1997) 103-107
3. Wilson J.E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206 (2003) 2049-2057
4. Tsai H.J., and Wilson J.E. Functional organization of mammalian hexokinases: characterization of chimeric hexokinases constructed from the N- and C-terminal domains of the rat type I and type II isozymes. Arch Biochem Biophys 316 (1995) 206-214
5. Tsai H.J., and Wilson J.E. Functional organization of mammalian hexokinases: both N- and C-terminal halves of the rat type II isozyme possess catalytic sites. Arch Biochem Biophys 329 (1996) 17-23
6. Tsai H.J., and Wilson J.E. Functional organization of mammalian hexokinases: characterization of the rat type III isozyme and its chimeric forms, constructed with the N- and C-terminal halves of the type I and type II isozymes. Arch Biochem Biophys 338 (1997) 183-192
7. Ardehali H., Yano Y., Printz R.L., Koch S., Whitesell R.R., May J.M., et al. Functional organization of mammalian hexokinase II. Retention of catalytic and regulatory functions in both the NH2- and COOH-terminal halves. J Biol Chem 271 (1996) 1849-1852
8. Pedersen P.L. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 22 (1978) 190-274
9. Warburg O, Dickens F, Kaiser Wilhelm-Institut für Biologie B. The metabolism of tumours: investigations from the Kaiser-Wilhelm Institute for Biology, Berlin-Dahlem. London: Constable; 1930.
10. Pedersen P.L., Mathupala S., Rempel A., Geschwind J.F., and Ko Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555 (2002) 14-20
11. Pedersen P.L. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39 (2007) 211-222
12. Bustamante E., and Pedersen P.L. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 74 (1977) 3735-3739
13. Bustamante E., Morris H.P., and Pedersen P.L. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256 (1981) 8699-8704
14. Nakashima R.A., Mangan P.S., Colombini M., and Pedersen P.L. Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N′-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. Biochemistry 25 (1986) 1015-1021
15. Nakashima R.A., Scott L.J., and Pedersen P.L. The role of mitochondrial hexokinase binding in the abnormal energy metabolism of tumor cell lines. Ann NY Acad Sci 488 (1986) 438-450
16. Mathupala S.P., Ko Y.H., and Pedersen P.L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25 (2006) 4777-4786
17. Di Chiro G., DeLaPaz R.L., Brooks R.A., Sokoloff L., Kornblith P.L., Smith B.H., et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32 (1982) 1323-1329
18. DeLaPaz R.L., Patronas N.J., Brooks R.A., Smith B.H., Kornblith P.L., Milam H., et al. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. AJNR Am J Neuroradiol 4 (1983) 826-829
19. Bustamante E., and Pedersen P.L. Mitochondrial hexokinase of rat hepatoma cells in culture: solubilization and kinetic properties. Biochemistry 19 (1980) 4972-4977
20. Arora K.K., and Pedersen P.L. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem 263 (1988) 17422-17428
21. Rempel A., Bannasch P., and Mayer D. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta 1219 (1994) 660-668
22. Rempel A., Bannasch P., and Mayer D. Microheterogeneity of cytosolic and membrane-bound hexokinase II in Morris hepatoma 3924A. Biochem J 303 (1994) 269-274
23. Mathupala S.P., Rempel A., and Pedersen P.L. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 270 (1995) 16918-16925
24. Johansson T., Berrez J.M., and Nelson B.D. Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma. Biochem Biophys Res Commun 133 (1985) 608-613
25. Magnuson M.A., Andreone T.L., Printz R.L., Koch S., and Granner D.K. Rat glucokinase gene: structure and regulation by insulin. Proc Natl Acad Sci USA 86 (1989) 4838-4842
26. Mathupala S.P., Heese C., and Pedersen P.L. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272 (1997) 22776-22780
27. Mathupala S.P., Rempel A., and Pedersen P.L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276 (2001) 43407-43412
28. Rempel A., Mathupala S.P., and Pedersen P.L. Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett 385 (1996) 233-237
29. Lee M.G., and Pedersen P.L. Glucose metabolism in cancer: importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter. J Biol Chem 278 (2003) 41047-41058
30. Goel A., Mathupala S.P., and Pedersen P.L. Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 278 (2003) 15333-15340
31. Rempel A., Mathupala S.P., Griffin C.A., Hawkins A.L., and Pedersen P.L. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 56 (1996) 2468-2471
32. Gatenby R.A., and Gawlinski E.T. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63 (2003) 3847-3854
33. Gillies R.J., Robey I., and Gatenby R.A. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 Suppl. 2 (2008) 24S-42S
34. Mathupala S.P., Colen C.B., Parajuli P., and Sloan A.E. Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr 39 (2007) 73-77
35. Graham J.F., Cummins C.J., Smith B.H., and Kornblith P.L. Regulation of hexokinase in cultured gliomas. Neurosurgery 17 (1985) 537-542
36. Gauthier T., Denis-Pouxviel C., and Murat J.C. Mitochondrial hexokinase from differentiated and undifferentiated HT29 colon cancer cells: effect of some metabolites on the bound/soluble equilibrium. Int J Biochem 22 (1990) 419-423
37. Miccoli L., Oudard S., Sureau F., Poirson F., Dutrillaux B., and Poupon M.F. Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J 313 (1996) 957-962
38. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15 (2001) 1406-1418
39. Robey R.B., and Hay N. Mitochondrial hexokinases: guardians of the mitochondria. Cell Cycle 4 (2005) 654-658
40. Pastorino J.G., and Hoek J.B. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 10 (2003) 1535-1551
41. Robey R.B., and Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25 (2006) 4683-4696
42. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899
43. Plas D.R., and Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24 (2005) 7435-7442
44. Zhou H., Hou Q., Chai Y., and Hsu Y.T. Distinct domains of Bcl-XL are involved in Bax and Bad antagonism and in apoptosis inhibition. Exp Cell Res 309 (2005) 316-328
45. Majewski N., Nogueira V., Bhaskar P., Coy P.E., Skeen J.E., Gottlob K., et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16 (2004) 819-830
46. Chiara F., Castellaro D., Marin O., Petronilli V., Brusilow W.S., Juhaszova M., et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS ONE 3 (2008) e1852
47. Baines C.P., Kaiser R.A., Sheiko T., Craigen W.J., and Molkentin J.D. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 9 (2007) 550-555
48. Ko Y.H., Pedersen P.L., and Geschwind J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173 (2001) 83-91
49. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324 (2004) 269-275
50. Cao X., Bloomston M., Zhang T., Frankel W.L., Jia G., Wang B., et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 14 (2008) 1831-1839
51. Park H.S., Chung J.W., Jae H.J., Kim Y.I., Son K.R., Lee M.J., et al. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. Korean J Radiol 8 (2007) 216-224
52. Penso J., and Beitner R. Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 342 (1998) 113-117
53. Goldin N., Arzoine L., Heyfets A., Israelson A., Zaslavsky Z., Bravman T., et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27 (2008) 4636-4643
54. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer cell 11 (2007) 37-51
55. Colen C.B., Seraji-Bozorgzad N., Marples B., Galloway M.P., Sloan A.E., and Mathupala S.P. Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 59 (2006) 1313-1323 (discussion 23-4)
56. Mathupala S.P., Parajuli P., and Sloan A.E. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 55 (2004) 1410-1419 (discussion 9)
57. Michelakis E.D., Webster L., and Mackey J.R. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99 7 (2008) 989-994
58. Fantin V.R., and Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 25 (2006) 4787-4797
59. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434
60. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008) 230-233